about
Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodiesAglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.CIG-DB: the database for human or mouse immunoglobulin and T cell receptor genes available for cancer studies.Fusogenics: a recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments.Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transferNatural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.Photochemical internalization of tumor-targeted protein toxins.Three-dimensional structure of the human myeloma IgG2.Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.Passive and active vaccination strategies to prevent ricin poisoning.Hendra and nipah infection: pathology, models and potential therapies.Agglutinating mouse IgG3 compares favourably with IgMs in typing of the blood group B antigen: Functionality and stability studies.Head and neck tumour immunology: basic concepts and new clinical implications.Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica.Antibody-based therapy of leukaemia.Recombinant antibodies: engineering and production in yeast and bacterial hosts.Lonely killers: effector cell- and complement-independent non-proapoptotic cytotoxic antibodies inducing membrane lesions.Molecular engineering of antibodies for therapeutic and diagnostic purposes.Therapeutic antibodies as a treatment option for dengue fever.Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers.The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytesInhibition of VEGF-dependent angiogenesis and tumor angiogenesis by an optimized antibody targeting CLEC14a.
P2860
Q27690917-57501048-8E64-44A8-86B8-2B12D617D417Q33524710-DAB9A790-C381-4F73-A2FB-96166FABF9F2Q33642275-FAB9C6D7-D934-4F14-95C3-A68A75B2A265Q33763294-9CD6693C-EF6F-41B4-BC09-FBD1E99B67D6Q33967100-9B24941C-EF0B-473D-9F24-C2828B34E6D0Q34005560-52831F9D-088C-45A9-8007-AF4EFB80F96CQ34034670-756E1795-DE5B-4FB4-8BB4-6C0F356A1356Q34068201-411E42DC-CC39-4D22-B348-269BC587265BQ34769388-922FB1F3-F65A-4F89-8066-1A614FC3A59EQ35018336-9A811445-FCC5-4069-BC6E-3E5660621275Q35459324-0096EEBB-FBDA-4994-A9DE-B89D27D41DFEQ35658146-C754F69F-FEDB-481F-9378-C00506F37C4DQ37147981-2104DA17-9381-468C-BC63-5440DB3C3DF1Q37257773-B0BAB748-F42E-4C70-9ADA-25A2702BC687Q37269115-890FF15B-21A3-445C-BB9A-3061C685E39DQ37472990-3E7F8DA3-6330-4F46-81C7-82EB4273C9B3Q37605247-B9D17921-D87B-4987-B31C-1921747BF7FCQ37822354-B7732BA7-61E0-45FB-B716-1087A1BC7C1EQ37962075-CC9688A7-A7BF-4706-94E6-F3EE9170FD35Q38017581-82C902BF-39DD-4C3D-9D7E-0C5B3527A7A3Q38149195-0B40AF99-E870-4384-8363-1CC685359D35Q38332777-7708A43F-D26B-450C-A8CF-5311538EF38EQ38355263-DEB69F00-9B5B-4568-AF64-3C5F4267198CQ41880647-586AD701-8F6F-4C97-A438-F4DC252B16E3Q50117760-1C8388A1-5B7B-4E6F-B9D5-345D18EF78EF
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Engineering therapeutic monoclonal antibodies.
@en
Engineering therapeutic monoclonal antibodies.
@nl
type
label
Engineering therapeutic monoclonal antibodies.
@en
Engineering therapeutic monoclonal antibodies.
@nl
prefLabel
Engineering therapeutic monoclonal antibodies.
@en
Engineering therapeutic monoclonal antibodies.
@nl
P2093
P2860
P1476
Engineering therapeutic monoclonal antibodies.
@en
P2093
Ellen S Vitetta
Laurentiu M Pop
Xiao-yun Liu
P2860
P356
10.1111/J.1600-065X.2008.00601.X
P577
2008-04-01T00:00:00Z